UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new long-term data from the BIMZELX® (bimekizumab) Phase 2b study BE AGILE and its...

Related Keywords

Brussels ,Bruxelles Capitale ,Belgium ,San Diego ,California ,United States ,Oregon ,Portland ,United Kingdom ,Antje Witte ,Musculoskelet Disord ,Emmanuel Caeymaex ,American College Of Rheumatology ,Immunology Solutions ,Division Of Arthritis ,Twitter ,Oregon Health Science University ,Us Communications ,American College ,Executive Vice President ,Professor Atul Deodhar ,Oregon Health ,Science University ,Rheumatic Diseases ,Ankylosing Spondylitis Disease Activity Score ,Bath Ankylosing Spondylitis Functional Index ,Ankylosing Spondylitis Quality ,All Candida ,Important Safety Information ,Herpes Simplex Infections ,Euronext Brussels ,Term Safety ,Active Ankylosing Spondylitis ,Year Results ,Axial Spondyloarthritis ,Ucb ,